KRYS - Krystal Biotech lays out catalysts for 2021

Today, in a regulatory filing, Krystal Biotech ([[KRYS]] +1.6%) disclosed the key milestones expected for the company’s pipeline in the year ahead. The timeline includes four data readouts, one trial initiation, and a possible IND filing.With topline data expected in 2H 2021, the pivotal Phase 3 (GEM-3) trial stands out from the rest as the company expects to complete its enrollment in Q1 2021.The multi-center, placebo-controlled, double-blinded study evaluates topical gene therapy bercolagene telserpavec (B-VEC) (previously KB103) for the treatment of dystrophic epidermolysis bullosa (“DEB”), a rare genetic disorder characterized by fragile skin that blisters easily.Having announced the initiation of Phase 1/2 study of KB105 in transglutaminase-1 (TGM1) deficient autosomal recessive congenital ichthyosis (“ARCI”), Krystal expects to announce the initial Phase 2 data and update on the next Phase 2 cohorts in 1H 2021.For KB407 targeting Cystic Fibrosis, the company is on track to disclose ‘IND-enabling’ preclinical data in 1H 2021 from a toxicology

For further details see:

Krystal Biotech lays out catalysts for 2021